UNSPSC 51151622: Bevonium

This classification denotes an anticholinergic agent with the molecular formula C22H28NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34B0471E08, chemically known as 2-(hydroxymethyl)-n,n-dimethylpiperidinium methyl sulfate benzilate but generally known as bevonium, which bears US NIH Compound Identifier 31800. bevonium most often comes in base and methyl sulfate forms, also called methylsulfate, methylsulphate, or even metilsulfate.

UNSPSC 51151622 Bevonium, a Commodity code, does not align with the state and local procurement activity tagged under it. The recent opportunities solicited under this code involve naloxone procurement and direct-to-manufacturer pharmacy initiatives — neither of which constitutes bevonium, a chemical element or compound outside the scope of typical state and local health or pharmaceutical purchases. The code shows little relevant recent activity; the tagging appears to reflect a classification mismatch rather than authentic demand for bevonium itself.

The two posted opportunities illustrate the actual buying pattern. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the county's community health building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding a direct-to-manufacturer prescription program for self-insured employee health plans, seeking information on vendors' experience with direct contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. Neither opportunity involves bevonium. State and local procurement under this code identifier should not be pursued without verification that the code has been correctly applied to actual bevonium-related solicitations.